BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
76.80
-0.56 (-0.72%)
At close: Nov 17, 2026, 4:00 PM EST
76.76
-0.04 (-0.05%)
After-hours: Nov 17, 2026, 5:52 PM EST

BridgeBio Pharma Revenue

BridgeBio Pharma had revenue of $353.17M in the quarter ending September 30, 2026, with 192.60% growth. This brings the company's total for the last twelve months to $945.54M, up 167.27% year-over-year. In the year 2025, BridgeBio Pharma had annual revenue of $502.08M with 126.26% growth. That makes BridgeBio Pharma the 7,909th largest company in the world by revenue and 1,837th in the United States.

Revenue (ttm)
$945.54M
Revenue Growth
+167.27%
P/S Ratio
15.75
Revenue / Employee
$871,465
Employees
1,085
Market Cap
14.96B

Revenue Chart

Revenue by Segment

By Segment

Chart
  • Net Product 362.37M 72.2%
  • License and Services 128.32M 25.6%
  • Royalty 11.39M 2.3%

By Geography

  • United States 362.50M 72.2%
  • Europe, Middle East, and Africa (EMEA) 127.03M 25.3%
  • Asia-Pacific (APAC) 12.55M 2.5%
Fiscal year ended Dec 31, 2025 See the full BridgeBio Pharma breakdown

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 2025502.08M280.17M126.26%
Dec 31, 2024221.90M212.60M2,285.27%
Dec 31, 20239.30M-68.35M-88.02%
Dec 31, 202277.65M7.93M11.38%
Dec 31, 202169.72M61.47M745.14%
Dec 31, 20208.25M-32.31M-79.66%
Dec 31, 201940.56M--
Dec 31, 2018---
Dec 31, 2017---

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.